UCB SA (OTCMKTS:UCBJF – Get Free Report) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $195.88 and last traded at $195.88, with a volume of 87 shares traded. The stock had previously closed at $174.00.
UCB Price Performance
The company has a 50 day moving average of $179.62 and a 200 day moving average of $164.54. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Canada Bond Market Holiday: How to Invest and Trade
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- How is Compound Interest Calculated?
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- What is Insider Trading? What You Can Learn from Insider Trading
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
